Dianthus Therapeutics, Inc. (DNTH), a clinical-stage biotechnology company, Monday announced positive top-line data from the Phase 2 MaGic trial evaluating claseprubart in adults with generalized Myasthenia Gravis (gMG). Following the news, the company's shares were more than 45% up in pre-market.
In the study, Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13. MG-ADL scale is used to measure gMG symptoms and QMG score is a tool to assess the severity of myasthenia gravis. Claseprubart also showed a rapid and sustained onset of action, with statistically significant improvements in MG-ADL and QMG scores at Week 1. Additonally, there were no drug-related serious adverse events. The company plans to initiate a Phase 3 study of claseprubart in gMG in 2026.
Dianthus Therapeutics stock had closed at $26.50, up 7.46% on Friday. It has traded in the range of $13.37 - $32.27 in the last 52 weeks.
For comments and feedback contact: editorial@rttnews.com
September 11, 2026 16:26 ET Consumer prices data was the main news on the economic front in the U.S. this week. In Europe, the latest interest rate decision from the European Central Bank was the focus along with the revised second quarter economic growth data for the euro area. In Asia, the monthly foreign trade data from China drew attention.